The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -0.41 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.35 — no flag raisedOK
- Earnings quality 78/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as TEVA PHARMACEUTICAL INDUSTRIES LTD reports it. History and quarterly detail are in the app.
- United States$9.2B
- Europe$5.0B
- International Markets$2.2B
- Other Activities$870.0M
Leadership changes
From TEVA PHARMACEUTICAL INDUSTRIES LTD's own filings, the day they're filed.
- Matthew Shields · President · appointmenteff. 2024-06-03
- Christine Fox · President · appointment
- S. Commercial · President · appointment
Latest filings
- 8-K · Company announcement2026-05-28
- 8-K · Company announcement2026-04-29
- 10-Q · Quarterly report2026-04-29
- DEF 14A · Annual proxy (pay & governance)2026-03-31
- 10-K · Annual report2026-02-03
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about TEVA PHARMACEUTICAL INDUSTRIES LTD, every answer cited🔒
- The Intelligence Brief — added when TEVA PHARMACEUTICAL INDUSTRIES LTD's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.